Dexamethasone and immunoglobulin for infection-related HLH
Part of Blood & lymphatic clinical trials.
This trial tests whether a short course of two medicines, dexamethasone (a steroid) and intravenous immunoglobulin (antibodies from donated blood), can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that is triggered by an infection. It may help control the body's overactive immune response and improve organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HLH that is likely caused by an infection (confirmed by a score of 80% or more)
- You have a known infection and either it's not getting better with antibiotics or you have new organ problems
- Your HLH is not caused by cancer, autoimmune disease, or Epstein-Barr virus
- You are not pregnant and have no HIV, liver or kidney disease, or allergy to the study medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Hear when a new Hemophagocytic Lymphohistiocytosis (HLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.